항균제 내성 진단 시장 규모, 점유율, 동향 분석 보고서 : 기술별, 병원체별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)
Antimicrobial Resistance Diagnostics Market Size, Share & Trends Analysis Report By Technology, By Pathogen, By End Use, By Region, And Segment Forecasts, 2026 - 2033
상품코드
:
1908189
리서치사
:
Grand View Research
발행일
:
2025년 12월
페이지 정보
:
영문 120 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
샘플 요청 목록에 추가
항균제 내성 진단 시장 개요
세계의 항균제 내성 진단 시장 규모는 2025년에 34억 2,000만 달러로 추정되며, 2033년에 46억 8,000만 달러에 달할 것으로 예측됩니다.
2026년부터 2033년까지 CAGR 4.08%로 성장할 것으로 예상됩니다. 폐렴구균, MRSA, 클로스트리디움 디피실 등 병원균의 높은 유병률과 더불어 항균제 내성(AMR) 감염증의 증가가 시장 확대를 크게 견인하고 있습니다.
미국 질병예방통제센터(CDC)에 따르면 미국에서는 연간 약 280만 건의 AMR이 발생하며, 미국약전협회(USP)의 보고에 따르면 AMR은 전 세계적으로 연간 약 70만 명의 사망을 초래하고 있습니다. 미생물 감염에 대한 적절한 진단과 치료가 이루어지지 않는다면 2050년까지 이 숫자는 1,000만 명에 달할 수 있습니다.
첨단 및 정확한 진단 솔루션에 대한 규제 당국의 승인 증가는 시장 수요 확대에 대응할 것으로 예상됩니다. 예를 들어, 2021년 10월 Hologic, Inc.는 유럽에서 Mobidiag Oy의 완전 자동화된 분자진단 시스템 'Novodiag'를 출시했습니다. 마이크로어레이 기술과 실시간 PCR 기술을 통합한 이 시스템은 항균제 내성 및 감염성 질환의 온디맨드 검사를 가능하게 하며, 단일 검체에서 여러 병원균을 식별할 수 있습니다. 또한, 같은 달 OpGen은 미국 FDA로부터 Acuitas AMR 유전자 패널 판매에 대한 510(k) 승인을 획득했습니다. 이 패널은 다양한 병원체에서 28종의 항균제 내성 유전자 마커를 검사하여 의료진이 내성균 감염을 관리하는데 도움을 줄 수 있습니다.
목차 제1장 조사 방법과 범위
제2장 주요 요약
제3장 항균제 내성 진단 시장 변수, 동향과 범위
시장 계통 전망
시장 역학
항균제 내성 진단 시장 분석 툴
산업 분석 : Porter's Five Forces
PESTEL 분석
제4장 항균제 내성 진단 시장 : 기술별, 추정·동향 분석
항균제 내성 진단 시장 : 기술 변동 분석
항균제 내성 진단 시장 : 기술별 전망
시장 규모 및 예측과 동향 분석(2021-2033년)
미생물 배양
면역측정법
PCR
차세대 시퀀싱(NGS)
질량 분석법
신속 검사·POC(Point of Care)
기타
제5장 항균제 내성 진단 시장 : 병원체별, 추정·동향 분석
항균제 내성 진단 시장 : 병원체 변동 분석
항균제 내성 진단 시장 : 병원체별 전망
시장 규모 및 예측과 동향 분석(2021-2033년)
약제 내성 폐렴구균(DRSP)
약제 내성 캄필로박터(DRC)
클로스트리듐 디피실(CD)
메티실린 내성 황색포도구균(MRSA)
약제 내성 임균(DRNG)
약제 내성 살모넬라균(DRNTS)
기타
제6장 항균제 내성 진단 시장 : 최종 용도별, 추정·동향 분석
항균제 내성 진단 시장 : 최종 용도 변동 분석
항균제 내성 진단 시장 : 최종 용도별 전망
시장 규모 및 예측과 동향 분석(2021-2033년)
병원
진단 실험실
제약 바이오테크놀러지 기업
기타
제7장 항균제 내성 진단 시장 : 지역별, 추정·동향 분석
지역별 대시보드
시장 규모와 예측 동향 분석, 2021-2033년
북미
유럽
영국
독일
프랑스
이탈리아
스페인
노르웨이
스웨덴
덴마크
포르투갈
튀르키예
스위스
벨기에
네덜란드
ROE
아시아태평양
일본
중국
인도
호주
한국
태국
말레이시아
인도네시아
베트남
기타 아시아태평양
라틴아메리카
브라질
아르헨티나
콜롬비아
페루
에콰도르
기타 라틴아메리카 국가
중동 및 아프리카
남아프리카공화국
사우디아라비아
아랍에미리트
쿠웨이트
제8장 경쟁 구도
시장 진입 기업 분류
주요 시장 진입 기업의 최근 동향과 영향 분석
기업 점유율 분석(2025년)
주요 기업 개요
bioMerieux
F. Hoffmann-La Roche Ltd
Abbott
BD
Danaher
Accelerate Diagnostics, Inc.
Molsid
Vela Diagnostics
Visby Medical, Inc.
Hologic, Inc.
OpGen.
Seegene Inc
EliTechGroup
CERTEST BIOTEC
KSM
영문 목차
Antimicrobial Resistance Diagnostics Market Summary
The global antimicrobial resistance diagnostics market size was estimated at USD 3.42 billion in 2025 and is expected to reach USD 4.68 billion by 2033, growing at a CAGR of 4.08% from 2026 to 2033. The high prevalence of pathogens such as Streptococcus pneumoniae, MRSA, and C. difficile, along with the increasing number of antimicrobial-resistant (AMR) infections, is significantly driving market expansion.
According to the CDC, approximately 2.8 million AMR cases occur annually in the U.S., and the U.S. Pharmacopeial Convention reports that AMR leads to around 700,000 deaths globally each year. This number could potentially rise to 10 million by 2050 if proper diagnosis and treatment of microbial infections are not implemented.
The rise in regulatory approvals for advanced and accurate diagnostic solutions is expected to meet the growing demand in the market. For example, in October 2021, Hologic, Inc. launched the fully automated Novodiag molecular diagnostic system from Mobidiag Oy in Europe. This system, which integrates microarray and real-time PCR technology, enables on-demand testing for antimicrobial resistance and infectious diseases, identifying multiple pathogens from a single sample. Additionally, in the same month, OpGen, Inc. received 510(k) clearance from the U.S. FDA to market its Acuitas AMR Gene Panel. This panel tests for 28 genetic antimicrobial resistance markers across various pathogens, aiding healthcare providers in managing resistant bacterial infections.
Global Antimicrobial Resistance Diagnostics Market Report Segmentation
This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the antimicrobial resistance diagnostics market report based on technology, pathogen, end use, and region:
Technology Outlook (Revenue, USD Million; 2021 - 2033)
Microbiology Culture
Immunoassay
PCR
NGS
Mass Spectrometry
Rapid & Point of Care
Others
Pathogen Outlook (Revenue, USD Million; 2021 - 2033)
Drug Resistant Streptococcus Pneumoniae (DRSP)
Drug Resistant Campylobacter (DRC)
Clostridium Difficile (CD)
Methicillin Resistant Staphylococcus Aureus (MRSA)
Drug Resistant Neisseria Gonorrhoeae (DRNG)
Drug Resistant Salmonella (DRNTS)
Others
End Use Outlook (Revenue, USD Million; 2021 - 2033)
Hospitals
Diagnostic Laboratories
Pharmaceutical & Biotechnology Companies
Others
Regional Outlook (Revenue, USD Million; 2021 - 2033)
North America
Europe
UK
Germany
France
Italy
Spain
Norway
Denmark
Sweden
Norway
Portugal
Turkey
Switzerland
Belgium
Netherlands
Rest of Europe
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Malaysia
Indonesia
Vietnam
Rest of Asia Pacific
Latin America
Brazil
Argentina
Colombia
Peru
Ecuador
Rest of Latin America
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Table of Contents Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Pathogen
1.2.3. End Use
1.2.4. Regional Scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR's internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Antimicrobial Resistance Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increase in risk of developing drug-resistant bacterial infections
3.2.1.2. Introduction of novel technologies to diagnose AMR infections
3.2.1.3. Favorable government initiatives
3.2.2. Market Restraint Analysis
3.2.2.1. Presence of stringent rules and regulations pertaining to diagnostics
3.3. Antimicrobial Resistance Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Antimicrobial Resistance Diagnostics Market: Technology Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Antimicrobial Resistance Diagnostics Market: Technology Movement Analysis
4.3. Antimicrobial Resistance Diagnostics Market by Technology Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
4.5. Microbiology Culture
4.5.1. Microbiology Culture Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Immunoassay
4.6.1. Immunoassay Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.2. PCR
4.6.2.1. PCR Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.3. NGS
4.6.3.1. NGS Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.4. Mass Spectrometry
4.6.4.1. Mass Spectrometry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.5. Rapid & Point of Care
4.6.5.1. Rapid & Point of Care Assays Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.6. Others
4.6.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Antimicrobial Resistance Diagnostics Market: Pathogen Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Antimicrobial Resistance Diagnostics Market: Pathogen Movement Analysis
5.3. Antimicrobial Resistance Diagnostics Market by Pathogen Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.5. Drug Resistant Streptococcus Pneumoniae (DRSP)
5.5.1. Drug Resistant Streptococcus Pneumoniae (DRSP) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Drug Resistant Campylobacter (DRC)
5.6.1. Drug Resistant Campylobacter (DRC) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Clostridium Difficile (CD)
5.7.1. Clostridium Difficile (CD) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Methicillin Resistant Staphylococcus Aureus (MRSA)
5.8.1. Methicillin Resistant Staphylococcus Aureus (MRSA) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.9. Drug Resistant Neisseria Gonorrhoeae (DRNG)
5.9.1. Drug Resistant Neisseria Gonorrhoeae (DRNG) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.10. Drug Resistant Salmonella (DRNTS)
5.10.1. Drug Resistant Salmonella (DRNTS) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.11. Others
5.11.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Antimicrobial Resistance Diagnostics Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Antimicrobial Resistance Diagnostics Market: End Use Movement Analysis
6.3. Antimicrobial Resistance Diagnostics Market by End Use Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.5. Hospitals
6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Diagnostic Laboratories
6.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Pharmaceutical & Biotechnology Companies
6.7.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Others
6.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Antimicrobial Resistance Diagnostics Market: Regional Estimates & Trend Analysis
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
7.4.9. Portugal
7.4.9.1. Key country dynamics
7.4.9.2. Regulatory framework/ reimbursement structure
7.4.9.3. Competitive scenario
7.4.9.4. Portugal market estimates and forecasts 2021 to 2033 (USD Million)
7.4.10. Turkey
7.4.10.1. Key country dynamics
7.4.10.2. Regulatory framework/ reimbursement structure
7.4.10.3. Competitive scenario
7.4.10.4. Turkey market estimates and forecasts 2021 to 2033 (USD Million)
7.4.11. Switzerland
7.4.11.1. Key country dynamics
7.4.11.2. Regulatory framework/ reimbursement structure
7.4.11.3. Competitive scenario
7.4.11.4. Switzerland market estimates and forecasts 2021 to 2033 (USD Million)
7.4.12. Belgium
7.4.12.1. Key country dynamics
7.4.12.2. Regulatory framework/ reimbursement structure
7.4.12.3. Competitive scenario
7.4.12.4. Belgium market estimates and forecasts 2021 to 2033 (USD Million)
7.4.13. Netherlands
7.4.13.1. Key country dynamics
7.4.13.2. Regulatory framework/ reimbursement structure
7.4.13.3. Competitive scenario
7.4.13.4. Netherlands market estimates and forecasts 2021 to 2033 (USD Million)
7.4.14. ROE
7.4.14.1. Key country dynamics
7.4.14.2. Regulatory framework/ reimbursement structure
7.4.14.3. Competitive scenario
7.4.14.4. ROE market estimates and forecasts 2021 to 2033 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
7.5.7. Malaysia
7.5.7.1. Key country dynamics
7.5.7.2. Regulatory framework/ reimbursement structure
7.5.7.3. Competitive scenario
7.5.7.4. Malaysia market estimates and forecasts 2021 to 2033 (USD Million)
7.5.8. Indonesia
7.5.8.1. Key country dynamics
7.5.8.2. Regulatory framework/ reimbursement structure
7.5.8.3. Competitive scenario
7.5.8.4. Indonesia market estimates and forecasts 2021 to 2033 (USD Million)
7.5.9. Vietnam
7.5.9.1. Key country dynamics
7.5.9.2. Regulatory framework/ reimbursement structure
7.5.9.3. Competitive scenario
7.5.9.4. Vietnam market estimates and forecasts 2021 to 2033 (USD Million)
7.5.10. Rest of APAC
7.5.10.1. Key country dynamics
7.5.10.2. Regulatory framework/ reimbursement structure
7.5.10.3. Competitive scenario
7.5.10.4. ROE market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
7.6.3. Colombia
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. Colombia market estimates and forecasts 2021 to 2033 (USD Million)
7.6.4. Peru
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Peru market estimates and forecasts 2021 to 2033 (USD Million)
7.6.5. Ecuador
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Ecuador market estimates and forecasts 2021 to 2033 (USD Million)
7.6.6. Rest of Latin America
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Rest of Latin America market estimates and forecasts 2021 to 2033 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Company Market Share Analysis, 2025
8.4. Key Company Profiles
8.4.1. bioMerieux
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. F. Hoffmann - La Roche Ltd
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Abbott
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. BD
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Danaher
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Accelerate Diagnostics, Inc.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Molsid
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Vela Diagnostics
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Visby Medical, Inc.
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Hologic, Inc.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
8.4.11. OpGen.
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product benchmarking
8.4.11.4. Strategic initiatives
8.4.12. Seegene Inc
8.4.12.1. Company overview
8.4.12.2. Financial performance
8.4.12.3. Product benchmarking
8.4.12.4. Strategic initiatives
8.4.13. EliTechGroup
8.4.13.1. Company overview
8.4.13.2. Financial performance
8.4.13.3. Product benchmarking
8.4.13.4. Strategic initiatives
8.4.14. CERTEST BIOTEC
8.4.14.1. Company overview
8.4.14.2. Financial performance
8.4.14.3. Product benchmarking
8.4.14.4. Strategic initiatives
관련자료
